VCYT (Veracyte) E10: $-0.59 (As of Mar. 2026)


VCYT Veracyte Inc VCYT
75 GF Score
Price $59.69
GF Value $38.10
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte E10?

Veracyte VCYT +5.16% 75 E10 is $-0.59 as of Mar. 2026. GuruFocus rates VCYT with a GF Score™ of 75/100 and a GF Value™ of $38.10 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Veracyte's adjusted earnings per share data for the three months ended in Mar. 2026 was $0.350. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.59 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 16.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Veracyte was 16.90% per year. The lowest was 16.90% per year. And the median was 16.90% per year.

As of today (2026-06-25), Veracyte's current stock price is $59.69. Veracyte's E10 for the quarter that ended in Mar. 2026 was $-0.59. Veracyte's Shiller PE Ratio of today is .


Veracyte  (NAS:VCYT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Veracyte E10 Related Terms


Veracyte E10 Historical Data

* Premium members only.

The historical data trend for Veracyte's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte E10 Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.15 -1.08 -0.90 -0.66

Veracyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.85 -0.81 -0.75 -0.66 -0.59

VCYT vs TWST, GRAL, RDNT: E10 Comparison

For the Diagnostics & Research subindustry, Veracyte's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Shiller PE Ratio falls into.


VCYT
75GF Score
Veracyte Inc VCYT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Veracyte's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.35/330.2130*330.2130
=0.350

Current CPI (Mar. 2026) = 330.2130.

Veracyte Quarterly Data

per share eps CPI Adj_EPS
201606 -0.400 241.018 -0.548
201609 -0.200 241.428 -0.274
201612 -0.140 241.432 -0.191
201703 -0.240 243.801 -0.325
201706 -0.220 244.955 -0.297
201709 -0.210 246.819 -0.281
201712 -0.240 246.524 -0.321
201803 -0.270 249.554 -0.357
201806 -0.180 251.989 -0.236
201809 -0.120 252.439 -0.157
201812 -0.080 251.233 -0.105
201903 -0.050 254.202 -0.065
201906 -0.050 256.143 -0.064
201909 -0.020 256.759 -0.026
201912 -0.150 256.974 -0.193
202003 -0.240 258.115 -0.307
202006 -0.220 257.797 -0.282
202009 -0.080 260.280 -0.101
202012 -0.140 260.474 -0.177
202103 -0.660 264.877 -0.823
202106 -0.130 271.696 -0.158
202109 -0.200 274.310 -0.241
202112 -0.150 278.802 -0.178
202203 -0.200 287.504 -0.230
202206 -0.130 296.311 -0.145
202209 -0.120 296.808 -0.134
202212 -0.050 296.797 -0.056
202303 -0.110 301.836 -0.120
202306 -0.120 305.109 -0.130
202309 -0.410 307.789 -0.440
202312 -0.390 306.746 -0.420
202403 -0.020 312.332 -0.021
202406 0.070 314.175 0.074
202409 0.190 315.301 0.199
202412 0.060 315.605 0.063
202503 0.090 319.799 0.093
202506 -0.010 322.561 -0.010
202509 0.240 324.800 0.244
202512 0.510 324.054 0.520
202603 0.350 330.213 0.350

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.59 mean?
Veracyte (VCYT) has a E10 of $-0.59 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Veracyte and its competitors.
Is Veracyte's E10 too high?
Veracyte's current E10 is $-0.59. Overall, Veracyte has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's E10 compare to TWST and GRAL?
Veracyte's E10 of $-0.59 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Diagnostics & Research company?
A good E10 depends on the Medical Diagnostics & Research industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Veracyte and its competitors. Veracyte's current E10 is $-0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Significantly Overvalued. The stock's GF Value™ is $38.10, compared to a current price of $59.69 — trading 56.7% above its estimated fair value. The current E10 is $-0.59. Veracyte's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Veracyte (VCYT), the current E10 is $-0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $59.69 is trading 56.7% above its estimated GF Value™ of $38.10. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for VCYT:

  • E10: $-0.59
  • GF Value™: $38.10 vs. price of $59.69 (56.7% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score

Get the complete analysis for VCYT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.69
Price
$38.10
GF Value